Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial ScienceDirect Novo Nordisk advances obesity candidate to late stage program after weight loss of less than 12% Cagrilintide is an amylin analogue that helps regulate appetite. In a randomized trial of over 3400 patients who were overweight or obese and had 1 weight related complication, individuals assigned to a combination BioCentury Early data from Novo's CagriSema competitive with Lilly's Mounjaro cagrilintide